Section
This cohort study reveals that clonal hematopoiesis of indeterminate potential (CHIP) independently increases age-related macular degeneration (AMD) risk, with amplified effects when combined with high genetic susceptibility, especially in
This study introduces CHIME, a novel HLA eplet mismatch model, revealing its association with non-relapse mortality and severe aGvHD in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide, improving
Oral decitabine/cedazuridine plus venetoclax provides an effective, fully oral frontline therapy for older or unfit patients with AML, showing encouraging response rates and manageable safety with long-term follow-up, highlighting particula
This article explores how decreased TXNRD1 expression and specific TET2 mutations are linked to tagraxofusp resistance in BPDCN patients, highlighting biomarkers that could guide future therapeutic strategies.
Recent findings identify a prevalent subset of platelet-activating antibodies in HIT that evade traditional PF4/heparin ELISA detection, highlighting new diagnostic and pathogenic insights.
This study validates the ISOLD score, a cytokine-based probabilistic tool, demonstrating high sensitivity and specificity for diagnosing vitreoretinal lymphoma from aqueous humor samples, outperforming standard IL-10/IL-6 ratios, with impli
The HLH-Risk-Calculator utilizes machine learning to predict initial disease severity and mortality at multiple time points in adult patients with secondary hemophagocytic lymphohistiocytosis, highlighting key biomarkers and advocating for
This article discusses a novel holistic H-score prognostic model integrating patient, disease, and treatment factors to predict leukemia-free survival after allogeneic transplantation in acute leukemia, enhancing risk stratification beyond
This article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.
This study highlights how linperlisib, a PI3Kδ inhibitor, enhances MUC1-Tn CAR T cell efficacy in T-ALL by preventing T cell exhaustion via suppression of the EGR1/DUSP2 pathway, improving anti-leukemic activity and persistence.
Development of engineered antibody fragments enables precise detection of pathogenic antibodies in heparin-induced thrombocytopenia, improving diagnosis and understanding of this immune-mediated blood disorder.
The Predictive Aplastic Score System (PASS) accurately distinguishes acquired aplastic anemia from inherited bone marrow failure syndromes using seven clinical variables, enabling rapid diagnosis and improved treatment decisions in adults.
Single-cell multiomic analysis reveals how genotype-immunophenotype relationships shape clonal evolution in NPM1-mutated acute myeloid leukemia, highlighting implications for prognosis and therapy response.
Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable surviva
CD79B expression in diffuse large B-cell lymphoma (DLBCL) exhibits a distinct gradient aligned with cell-of-origin subtypes and germinal center B-cell differentiation stages, highlighting the biological basis for differential therapy respon
EBV-positive diffuse large B-cell lymphoma exhibits severe systemic antiviral T-cell impairments and a suppressive tumor microenvironment driven by LMP1, revealing novel immunobiological insights with therapeutic implications.
Shorter diagnosis-to-treatment intervals independently predict worse outcomes in follicular lymphoma treated with immunochemotherapy, highlighting a novel prognostic factor beyond existing risk indices.
Fecal calprotectin offers a non-invasive, dynamic biomarker to predict, diagnose, and monitor GI-GVHD post-allo-HSCT, correlating with endoscopic severity and treatment response, but requires integrated clinical interpretation due to limite
Dual inhibition of CDK2 and CDK4/6 demonstrates synergistic anti-leukemic effects in AML by suppressing the Rb/E2F axis, offering a promising therapeutic strategy to improve outcomes in this challenging hematologic malignancy.
The EURO-SKI Biomarker Study elucidates molecular signatures and immune interactions underlying treatment-free remission and relapse in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors, highlighting immune communic
